Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

724 results about "Cell preparation" patented technology

Cytotherapeutics, cytotherapeutic units and methods for treatments using them

ActiveUS20070092497A1Uniform and effective therapeutic applicationMinimal numberBiocideSenses disorderAssayTreatment use
The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
Owner:CELULARITY INC

Secondary Cell Preparation for Inter-Site Carrier Aggregation

According to embodiments of the invention, an apparatus is provided which includes a connection unit configured to send and / or receive data to and / or from a secondary network control node, a processor configured to establish a configuration preparation message for the secondary network control node for preparing a carrier aggregation in which data to a user equipment is transmitted by at least two component carriers, and in which at least one first component carrier is provided between the apparatus and the user equipment and at least one second component carrier is provided between the secondary network control node and the user equipment, wherein the configuration preparation message includes configuration preparation information for the carrier aggregation, and the connection unit is configured to send the configuration preparation message to the secondary network control node.
Owner:NOKIA TECHNOLOGLES OY

Multipotent Adult Stem Cells And Uses of Multipotent Adult Stem Cells To Treat Inflammation

Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and / or fibrosis, promote would healing, repair epithelial damage, and / or promote angiogenesis.
Owner:MESOBLAST INT

Cell Preparations for Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides compositions comprising plasma or platelet-rich plasma alone or in combination with cell preparations for use in tissue regeneration and bone regeneration and pain reduction.
Owner:REGENLAB USA LLC

Disease therapy using dying or dead cells

A method of treating a disease characterized by a pathological immune response in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a cell preparation which comprises dying or dead leukocytes, the dying or dead leukocytes being capable of suppressing the pathological immune response, thereby treating the disease in the subject.
Owner:ENLIVEX THERAPEUTICS LTD

CIK cell, as well as preparation method and cell preparation thereof

The invention discloses a CIK cell, as well as a preparation method and a cell preparation thereof. The method for preparing the CIK cell comprises the following steps: placing a separated mononuclear cell in a culture fluid containing phytohemagglutinin; transplanting the mononuclear cell into a culture flask enveloped by antiCD3 monoclonal antibody and antiCD28 monoclonal antibody after the cell is cultured for 24 to 72 hours; and adding a culture fluid containing IL-1alpha and IL-2 into the culture flask to keep on culturing for 5 to 15 days, and separating the cells into different flasks to be cultured every 2 to 3 days. The CIK cell prepared by the method has the characteristics of obvious improved cell proliferation, great increase of CD8 cell proportion, wide antineoplastic spectrum and strengthened antineoplastic activity. The CIK cell and the cell preparation can effectively prevent the metastasis and the recrudescence for of postoperative patients with tumor, can be combined with chemicotherapy to effectively reduce toxic and side effects of the chemicotherapy, strengthens the survivability tolerance of the patients to improve healing efficacy, and can obviously prolong lifecycle to of end-stage patients so as to improve the life living quality.
Owner:上海德嘉生物科技有限公司 +1

Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells

InactiveUS20080038314A1Effective therapeutic compositionEfficient methodPeptide/protein ingredientsBone implantActive agentSynovial Cell
Compositions and methods are provided for treatment of cartilage defects in animals and humans. The compositions of the invention include synovial tissue, synovial cells and matrices containing synovial (or cambium) tissue or cells for use in filling a cartilage defect. The matrix and synovial tissue or cell preparations may also contain a proliferation agent, transforming factor or other active agents to promote healing. A controlled-release delivery system may be used to administer the transforming factor. The compositions of the invention also include a synovial covering membrane or devitalized fascial sheet for covering the cartilage defect. The methods of this invention are those in which a minimally invasive surgical intervention is performed to remove a small portion of synovial membrane from a joint. Portions of the synovial membrane, or cells expanded in vitro, are implanted alone or within a matrix, into the defect site, where they produce new cartilage tissue and repair the defect. Alternatively, partially transformed synovial-derived tissue may be formed in situ and implanted into the defect site.
Owner:ORTHOGENE

Process for producing succinic acid

Succinic acid is produced by allowing a bacterium modified to enhance fumarate reductase activity or cell preparation thereof to react with an organic raw material in a reaction solution containing one of a carbonate ion, a bicarbonate ion, and carbon dioxide gas to generate succinic acid. More preferably, succinic acid is produced by allowing a bacterium modified to enhance activities of fumarate reductase and pyruvate carboxylase and decrease lactate dehydrogenase activity or cell preparation thereof to react with an organic raw material in a reaction solution containing one of a carbonate ion, a bicarbonate ion, and carbon dioxide gas to generate succinic acid. Succinic acid is obtained by collecting the produced succinic acid.
Owner:AJINOMOTO CO INC

Cell preparation for treating osteoarthritis and preparation method thereof

The invention provides a cell preparation for treating osteoarthritis and a preparation method thereof. The cell preparation mainly comprises mesenchymal stem cells, differentiation-induced stem cells, platelet-rich plasma and dispersion media thereof. Compared with the prior art, the cell preparation for treating osteoarthritis has the advantages that the mesenchymal stem cells are mixed with the differentiation-induced stem cells and compounded with the platelet-rich plasma and can be dispersed in the joint cavity, so that the immune regulation function of the mesenchymal stem cells can be exerted, the microenvironment of the whole joint cavity can be improved, and inflammation remission and injury repair are facilitated; tissues can be repaired after the differentiated mesenchymal stem cells are implanted into the body, so that the repair process is shortened.
Owner:广东佰鸿干细胞再生医学有限公司

Use of cells with the ability to generate excitation within a cell preparation

Cells with the capability to generate excitation in a heart muscle tissue are used in this invention as biological cardiac pacemakers. That is done by suspending the dissociated cells and injecting them at a suitable position into the heart of a patient. The suspension can contain medicinal additives.
Owner:HAVERICH AXEL +1

Tumor specific killer cell preparation and preparation method thereof

The invention relates to a tumor specific killer cell preparation and a preparation method thereof. A specific killer cell is a mixture of DC (Dendritic Cell) vaccine, and CIK (Cytokine Induced Killer) and CTL (Cytotoxic Lymphocyte) cells. The preparation contains thymopentin; the preparation is mixed with the killer cells so as to have the effect of obviously improving the treatment effect.
Owner:浓孚雨医药河北有限公司

Method for amplifying cytokine induced kill cells (CIK) and CIK cell preparation

ActiveCN102352342AStrong mitogenic effectIncrease the level of amplificationMammal material medical ingredientsBlood/immune system cellsPeripheral blood mononuclear cellCell separation
The invention relates to a method for amplifying cytokine induced kill (CIK) cells and a CIK cell preparation, which belong to the field of in-vitro culture of immune cells. The method concretely adopts the following procedures that: a, lymphocyte cell separation liquid is used for separating out peripheral blood mononuclear cells (PBMC), a culture bag is covered by CD3mAb and CD137mAb in advance, the concentration of the PBMC obtained through separation is regulated to 1*10<6> / ml by a serum-free culture medium, in addition, IFN-gamma is added to obtain the final concentration being 1000 mu / ml, and the materials are transferred to the culture bag to be cultured; b, CD3mAb, CD28mAb and CD137mAb are added after the culture for 24h, in addition, the prepared serum-free culture medium is added, IL-1alpha, IL-2, IL-12 and IL-15 are added into the prepared serum-free culture medium, and obtained CIK cells are collected through centrifugation after the continuous culture for 7 to 21 days; and c, in the culture process of the step b, the cells in the culture bag are counted every three days, in addition, the culture medium is supplemented according to the concentration of the cells, and the CD3mAb, the CD28mAb and the CD137mAb are added to the corresponding concentration every six days, so the CIK cell generative cell times and the cytotoxin activeness are improved.
Owner:SHANGHAI CLAISON BIOTECH

Methods and Systems for Treating Injured Cardiac Tissue

Methods and systems are disclosed for treating cardiac tissue by delivering a platelet composition which induces neovascularization in the cardiac tissue followed by a cell preparation which induces regeneration in the re-vascularized tissue. The platelet composition can additionally contain structural materials and / or bioactive agents.
Owner:MEDTRONIC VASCULAR INC

Cell preparations comprising cells of the T cell lineage and methods of making and using them

The invention relates to cell preparations comprising cells of the T cell lineage, methods for preparing same, and uses of the cell preparations.
Owner:SUNNYBROOK HEALTH SCI CENT

In vitro culture-amplified human liver progenitor cell and preparation thereof

The present invention provides a preparing method of a human hepatic progenitor cell which is amplified and cultivated in vitro, including: a. separating the human hepatic progenitor cell; b. co-cultivating a feeder cell and the human hepatic progenitor cell separated from the step a by a medium having no serum on an extracellular matrix containing human fibrin sealant or other analogues, obtaining a human hepatic progenitor cell colony by amplification. The human hepatic progenitor cell colony is easy to separate from the surface of human fibrin sealant by the simple gelatinolytic band process, purified or / and subcultured by further single cell preparation technology process such as enzymatic degradation etc. The human hepatic progenitor cell prepared by the method is hepatic progenitor cell treatment, including a cell transplantation and a bioartificial liver support system, providing excellent human hepatocyte source for cytotoxicity test platform in the drug screening, virus infection and drug screening platform etc.
Owner:芦银雪

Device for cell spraying, manufacturing of the device, method for spraying with the device and a cell suspension sprayed with the device

The invention provides a description of a method and a device suitable for producing a cell suspension spray with living cells, and the produced cell preparation, suitable for grafting to a patient. In contrast to other methods, the spraying is performed through a disposable needle which is inserted into a disposable air tube; which provides a cell distribution avoiding spray nozzles. Small suspension droplets are provided instead of cell nebulization. By using medical grade sterile Luer-lock disposables from medical routine praxis, biocompatibility and easy application is addressed. In applying the method and / or in using the device, cells suitable for grafting to a patient are dispersed in a solution and sprayed with the device for distribution over the recipient graft site.
Owner:RENOVACARE SCI

Mixing stem cell injection and preparation method thereof

The invention discloses a mixing stem cell injection and a preparation method thereof, and belongs to the field of cell preparation agents. The injection of the invention is mixture of mesenchymal stem cells from umbilical cord source and hematopoietic stem / progenitor cells from the umbilical cord blood source; the method of the mixing stem cell injection comprises the following steps: CD34+ hematopoietic stem cells are separated from the fresh umbilical cord blood and purified, and are subjected to mixed culture and amplification together with the mesenchymal stem cells from the umbilical cord source, during the amplification, the culture system is culture medium including AB umbilical cord blood plasma the volume fraction of which is 15 percent and the cell factor, 6*104 mesenchymal stem cells and CD34+ hematopoietic stem cells with the concentration of 5*104 / ml are inoculated into a culture flask and are cultured for about 10 days, and two kinds of cells are obtained at the same time, so that the mixed stem cell injection including 5*105 / ml of hematopoietic stem / progenitor cells and 2*105 / ml of mesenchymal stem cells and containing normal saline with the volume fraction of AB umbilical cord blood plasma as 15 percent is obtained.
Owner:广州市天河诺亚生物工程有限公司

Method for simultaneously extracting epithelial cells and mesenchymal stem cells from umbilical cord and placenta amnion tissues

The invention relates to a method for simultaneously extracting epithelial cells and mesenchymal stem cells from umbilical cord and placenta amnion tissues. The method comprises the steps of (1) sampling umbilical cord and placenta amnia and inoculating; (2) performing amplifying and passage on mesenchymal stem cells and amnion epithelial cells in a culture flask; (3) identifying the mesenchymal stem cells and the amnion epithelial cells: 1) when culture cells is transferred to the third generation, identifying the purity of culture cells after trypsinization; 2) verifying the cell purity to be 90 percent or more, namely the standard is met, and a mixture of the epithelial cells and the mesenchymal stem cells is obtained. The method is low in cost, simple and rapid, umbilical cord and placenta amnia are cut into tiny pieces by using a tissue cutting machine, which is conducive to swimming out of the tissues after the cells are directly inoculated in the culture flask; the cost is greatly lowered due to the fact that no proteinase reagent is used, and the preparation time is reduced, so that large-scale cell preparation in short time is realized; the method uses cell culture mediums being added with growth factors and other nutrients, and serum is saved.
Owner:斯坦姆(天津)生物技术研究有限公司

Efficient CIK amplifying method

The invention discloses an efficient CIK amplifying method, in particular to a method for cell populations, namely cytokine-induced killer cells utilizing in-vitro cell factors for efficiently inducing mononuclear cell expressions CD3 and CD56 of peripheral blood, wherein the cell populations have killing functions. The cultivation method for the CIK efficiently expressing CD3+CD56 comprises the following steps that the peripheral blood of a healthy person or a patient is collected in a sterile mode, after the peripheral blood is diluted through a saline solution with the same volume, a Ficoll lymphocyte separating medium is used for separating mononuclear cells, in the CIK cell inducing process, CD3 monoclonal antibodies (CD3mAb), CD28 monoclonal antibodies (CD28mAb), interferon-gamma (IFN-gamma), interleukin-2(IL-2) and interleukin 1alpha (IL-1alpha) are added, cultivation is carried out for 13-16 days to obtain cells, a CIK cell preparation is prepared, and flow cytometry detection and microorganism detection are carried out. According to the CIK cultivation method, the CIK number can be increased to be 6*10<9> or over 6*10<9> in two weeks, the cell survival rate can be increased to be 99% or over 99%, and the double-positive proportion of the CD3+CD56+cells reaches 30% or over 30%.
Owner:UNION STEMCELL & GENE ENG

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides compositions comprising plasma or platelet-rich plasma alone or in combination with cell preparations for use in tissue regeneration and bone regeneration and pain reduction.
Owner:REGENLAB USA LLC

Adult Stem Cell-Derived Connective Tissue Progenitors for Tissue Engineering

Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from adult stem cells are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.
Owner:TECHNION RES & DEV FOUND LTD

Method for inducing differentiation into epithelial progenitor cell/stem cell population and corneal epithelial cell population from induced pluripotent stem cells

The present invention relates to: a method for inducing differentiation into an epithelial progenitor cell / stem cell population or a corneal epithelial cell population by culturing, under particular conditions, induced pluripotent stem cells induced from mammalian somatic cells or undifferentiated stem cells; an epithelial progenitor cell / stem cell population or a corneal epithelial cell population obtained by the method; and a cell preparation for the treatment of epithelial disease and a cell sheet, which are prepared using these cell populations.
Owner:TOHOKU UNIV +1

Use of human fat-derived mesenchymal stem cells in treatment of diseases in kidney and ocular fundus

The invention relates to the use of human fat-derived mesenchymal stem cells in the treatment of diseases in kidney and ocular fundus. The invention provides the use of the human fat-derived mesenchymal stem cells in cell preparation for treating diseases in kidney and / or ocular fundus, such as acute kidney injury, renal fibrosis, renal tubular epithelial cell damage, retinosis, diabetic retinopathy and retinal tear. The cell preparation can promote the repair of kidney structure and damaged eyeball pathologic structure with good effect.
Owner:微能生命科技集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products